Newest Reaserch Advance in treatment of Plasmablastic lymphoma--Review.
10.19746/j.cnki.issn.1009-2137.2020.04.056
- Author:
Dan LIU
1
;
Xiao-Hui HE
2
;
Yun-Xia TAO
1
;
Sheng YANG
1
Author Information
1. Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
2. Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China,E-mail：xiaohuih2008@163.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Plasmablastic Lymphoma
- From:
Journal of Experimental Hematology
2020;28(4):1410-1413
- CountryChina
- Language:Chinese
-
Abstract:
Plasmablastic lymphoma(PBL) shows a low incidence and poor prognosis, moreover, there is no standard treatment regimen for PBL. The treatment effect and value of CHOP regimen and radiotherapy are limited. Some studies showed that intensive chemotherapy alone or its combination with proteasome inhibitors or immune regulator can improve the overall survival of patients with PBL, which can be used as the first-line therapy for PBL patients. CAR-T and immunocheckpoint inhibitors showed treatment effect for the patients with refractory and relapsed plasmablastic lymphoma. The clinical value of potential targets in treating tumour worth to be studied further.
